On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals (NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, Acorn Capital Advisors reduced its position in Terns Pharmaceuticals (NASDAQ:TERN) by 225,000 shares during the fourth quarter of 2025. The estimated value of the trade was approximately $5.20 million, calculated using ...